Please login to the form below

Not currently logged in
Email:
Password:

Metrion Biosciences adds to its board

Dr Barry Kenny and Dr Andrew Southan join the company

Metrion Biosciences, the specialist ion channel contract research and drug discovery group, has appointed Dr Barry Kenny and Dr Andrew Southan to its board of directors, a move that will see the group strengthen the company’s focus on commercial and business development capabilities.

Dr Kenny is currently chief business officer of Heptares Therapeutics, now part of Sosei Group, and was previously vice president, drug discovery at Takeda.

He has held roles for Paradigm Therapeutics and Pfizer.

Dr Southan joined Metrion as head of commercial operations in October 2016, and was promoted to chief operating officer in April 2017.

He has over 25 years’ experience in ion channel research and development and has held roles for Wyeth Research and Ionix Pharmaceuticals.

Dr Keith McCullagh, non-executive chairman of Metrion Biosciences, said: “I am delighted to welcome both Barry and Andy to Metrion’s board of directors.

“Barry’s substantial experience of drug discovery deal-making will be of great value to Metrion as we continue to build our worldwide CRO and collaboration business, and Andy’s dedication to Metrion’s client service and quality of operations has been a major factor of growth of the business.”

20th March 2018

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...